期刊文献+

1,25-(OH)2D3负向调节糖尿病模型大鼠血管紧张肽活性 被引量:3

1,25-Dihydroxyvitamin D_3 is a Negative Regulator for the Activation of Angiotonin
暂未订购
导出
摘要 目的研究1,25-(OH)2D3对糖尿病(DM)模型大鼠肾素-血管紧张肽-醛甾酮系统(RAAS)活性的影响及对肾小球足细胞的保护作用。方法将40只SD大鼠分为正常对照组(A组)、糖尿病组(B组)、血管紧张肽Ⅱ(AngⅡ)灌注组(C组)、AngⅡ+1,25-(OH)2D3灌注组(D组)。B、C、D组均腹腔注射链脲菌素(STZ)制作DM大鼠模型。C组皮下埋置渗透性微量泵,给予AngⅡ400ng·kg-1·min-1;D组经两条渗透性微量泵通路分别给予AngⅡ(400ng·kg-1·min-1)+1,25-(OH)2D3(450ng·kg-1·min-1)。两组均连用10周。检测大鼠血糖(BG)、收缩压(SBP)、24h尿蛋白定量(TP)和肾素活性(PRA)、血管紧张肽Ⅱ(AngⅡ)和醛甾酮(Ald)水平。检测尿沉渣足细胞特异性标志蛋白podocalyxin以检测尿液足细胞(UPC)水平,免疫荧光染色观察肾小球上皮细胞蛋白-1(GLEPP1)的分布。结果B组BG、SBP、UPC、TP、PRA、AngⅡ、Ald均较A组明显升高。C组SBP、UPC、TP、PRA、AngⅡ、Ald较B组均明显升高(P<0.05或P<0.01)。D组SBP、UPC、TP、AngⅡ、Ald较C组明显降低,D组AngⅡ较B组明显降低。病理组织肾小球荧光染色示A组GLEPP1正常分布,C组呈明显缺失,B和D组亦缺失。UPC与TP、AngⅡ呈正相关(rs=0.51,0.35,P<0.01,P<0.05)。结论1,25-(OH)2D3可能是RAAS的负向调节因子,通过下调RAAS活性,防止足细胞脱落排泄介导其肾保护作用。 Objective To investigate the influence of 1,25-dihydroxyvitamin D3 [ 1,25-(OH)2D3 ] on the activation of the renin angiotensin aldosterone system(RAAS) in rats with diabetes mellitus (DM), and the protection on podocyt. Methods SD rats were divided into four groups, normal control group(group A), DM group(group B) , angiotensin Ⅱ (Ang Ⅱ )group ( group C) , and Ang Ⅱ combined with 1,25- (OH)2O3 ( group D) group. DM rats were induced by i.p. streptozotocin (STZ). Group C was embedded with the osmotic minipump for giving 400 ng·kg^-1·min^-1 Ang Ⅱ. Group D was given 400 ng·kg^-1·min^-1 AngⅡ and 450 ng · kg^-1·min^-1 1,25-( OH)2 D3 by two osmotic minipumps. Blood glucose(BG), contractive pressure(SBP) ,24 h total proteinuria (TP) ,the activation of renin, the level of Ang Ⅱ and aldosterone(Aid) were measured after 10 week's treatment. The podocalyxin( PCX, podocyte-specific marker) was detected to identity the urinary podocytes(UPC) and the distribution of glomerular epithelial cell membrane protein-1 ( GLEPP1 ) was observed by jmmunofluorescene. Results BC,SBP, UPC, TP,PRA,AngⅡ and Aid in group B were significantly higher than those in group A. SBP, UPC,TP,PRA,Ang Ⅱ and Ahl in group C were significantly raised compared with those in group B (P 〈0.05 or P 〈0.01 ). SBP, UPC ,TP,Ang Ⅱ and Aid in group D were significantly lower than those in group C. Ang Ⅱ in group D was significantly lower than that in group B. Histologically, the distribution of GLEPP1 in glomeruli was normal in group A by immunofluorescene, obviously absence in group C, and absence in group B and D. The positive correlations were found between the levels of UPC with TP( r = 0.51,P 〈 0.01 ) and AngⅡ (r =0.35,P〈0.05). Conclusion 1,25(OH)2D3 may be a negative regulator for the renin-angiotensin system by down-regulating the activity of RAAS to prevent the defluvium and excretion of podocyte, which mediating its renal protective effects.
出处 《医药导报》 CAS 2008年第5期530-533,共4页 Herald of Medicine
关键词 1 25-(OH)2D3 糖尿病 足细胞 血管紧张肽Ⅱ 1,25-(OH)2D3 Diabetes mellitus Podocyte Angiotensin Ⅱ
  • 相关文献

参考文献11

  • 1陈兰,李国贤,郭汉城.肾小球肾炎足细胞脱落与肾组织钠氢交换调节因子2表达的研究[J].临床肾脏病杂志,2006,6(6):245-248. 被引量:5
  • 2WHARRAM B L, GOYAL M,WIGGINS J E,et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene [ J ]. J Am Soc Nephrol , 2005,16(10) :2941 - 2952.
  • 3王文姬,陈楠.活性维生素D_3与肾脏病[J].肾脏病与透析肾移植杂志,2006,15(3):262-265. 被引量:12
  • 4NAKAMURA T, USHIYAMA C, HIROKAWA K,et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis [ J 1. Nephrol Dial Transplant ,2002,17:798 - 802.
  • 5TRYGGVASON K, WARTIOVARA J. How does the kidney filter plasma? [ J ]. Physiology,2005,20:96 - 101.
  • 6TAKANO K, KAWASAKI Y, IMAIZUMI T, et al. Development of glomerular endothelial cells, podocytes and mesangial cells in the human fetus and infant [ J ]. Tohoku J Exp Med, 2007,212( 1 ) :81 -90.
  • 7KIM Y H,GOYAL M,KURNIT D,et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat [ J ]. Kidney Int,2001,60:957 - 968.
  • 8HOFFMANN S, PODLICH D, HAHNEL B,et al. Angiotensin Ⅱ type 1 receptor overexpression in podoeytes induces glomerulosclerosis in transgenic rats [J]. J Am Soc Nephrol, 2004,15 : 1475 - 1487.
  • 9GROSS M L, EL-SHAKMAK A, SZABO A, et al. ACE- inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy [ J ]. Diabetologia, 2003,46:856 - 868.
  • 10TIAN J, LIU Y, WILLIAMS L A, et al. Potential role of active vitamin D in retarding the progression of chronic kidney disease [ J ]. Nephrol Dial Transplant, 2007,22 (2) : 321 - 328.

二级参考文献46

  • 1邓江红,丁洁,管娜,苗鸿才,汤秀英.嘌呤霉素肾病鼠足突形态改变的形态计量学研究[J].中国体视学与图像分析,2003,8(1):9-15. 被引量:18
  • 2章友康 王海燕 王叔咸.用嘌呤霉素制作氨基核苷肾病模型[J].中华肾脏病杂志,1986,2:226-228.
  • 3Smeets B, Nathalie AJM, Henry BPM, et al. The parietal epithelial cell: a key player in the pathogenesis of focal segmental glomerulosclerosis in Thy-1.1 transgenic mice.J Am Soc Nephrol, 2004,15:928-939.
  • 4Vogelmann SU, Nelson WJ, Myers BD, et al. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol, 2003,258:40-48.
  • 5Takeda T, McQuistan T, Robert AO, et al. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest, 2001, 108: 289-301.
  • 6Kriz W. Progressive renal failure-inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transpl, 1996,9:1738-1742.?A
  • 7Nakamura T, Ushiyama C, Suzuki S, et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal change nephrotic syndrome. Am J Nephrol, 2000, 20: 175-179.
  • 8Dontscho K. Caught flat-footed podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest,2001,108:1583-1587.
  • 9Diamond JR,Karnovsky MJ.Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am J Pathol, 1986, 122: 481-487.
  • 10Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol,2002,13:3005-3015.

共引文献29

同被引文献36

  • 1Tanuj Chawla,Deepika Sharma,Archana Singh.Role of the renin angiotensin system in diabetic nephropathy[J].World Journal of Diabetes,2010,1(5):141-145. 被引量:36
  • 2赵卫红.维生素D基因多态性与慢性肾功能衰竭继发性甲旁亢的关系[J].国际泌尿系统杂志,2003,23(S1):57-59. 被引量:1
  • 3刘桂萍.1,25—二羟基维生素D_3的研究进展[J].生物学教学,1994,19(4):4-6. 被引量:3
  • 4LI Y C, KONG J, WEI M, et al. 1,25-Dihydroxyvitamin D (3) is a negative endocrine regulator of the renin- angiotensin system [ J ]. J Clin Invest, 2002,110 (2) : 229- 238.
  • 5ZHANG Y, KONG J, DEB D K,et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin- angiotensin system [ J ]. J Am Soc Nephrol, 2010,21 (6) : 966-973.
  • 6FINCH J L, SUAREZ E B, HUSAIN K, et al. Effect of com- bining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats [ J ]. Am J Physiol Renal Physiol, 2012,302 (1) :141-149.
  • 7SANCHEZ-NINO M D, BOZIC M, CORDOBA-LANUS E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy [ J ]. Am J Physiol Renal Physiol,2012,302(6) :647-657.
  • 8ZHANG Z, SUN L, WANG Y,et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy[ J ]. Kidney Int,73(2) :163-171.
  • 9OHARA I, TANIMOTO M, GOHDA T, et al. Effect of com- bination therapy with angiotensin receptor blocker and1,25- dihydroxyvitamin D (3) in type 2 diabetic nephropathy in KK-A (y)/Ta mice [ J ]. Nephron Exp Nephrol, 2011,117 (4) :124-132.
  • 10KONG J, KIM G H, WEI M, et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats[ J]. Am Pathol,2010,177 (2) :622- 631.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部